Nusano Announces Series C Financing of Over $115M to Commercialize Radioisotopes

by Scott Larrivee | Oct 1, 2024 | News

Funding supports development and commercialization of broad array of isotopes for medical, commercial and industrial uses VALENCIA, Calif. – Oct. 1, 2024 – Nusano, Inc., a physics company transforming the production of radioisotopes, today announced a Series C...

Nusano Named to Insights Care 5 Most Trusted Radiopharmaceutical Companies to Watch

by Scott Larrivee | Sep 27, 2024 | Blog, Awards & Honors

September 2024 – Insights Care recently interviewed Nusano CEO Chris Lowe for its “5 Most Trusted Radiopharmaceutical Companies to Watch” edition. Lowe discussed the urgent need for new medical radioisotope supplies, how Nusano will be part of the...

Nusano and PharmaLogic Announce Strategic Supply Agreement to Enable Current and Emerging Radiopharmaceuticals

by Scott Larrivee | Jul 10, 2024 | News

VALENCIA, Calif. and BOCA RATON, Fla. – July 10, 2024 – Nusano Inc. (Nusano), a physics company transforming the production of medical radioisotopes, and PharmaLogic Holdings Corp. (PharmaLogic), a leading radiopharmaceutical contract development and manufacturing...

Nusano to Present at Jefferies Radiopharma Innovation Summit

by Scott Larrivee | Apr 10, 2024 | News

VALENCIA, Calif. – April 10, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced it will attend and present at Jefferies Radiopharma Innovation Summit in New York City on Thursday, April 11, 2024. In his presentation,...

Nusano to Participate in the B. Riley Securities Radiopharma Investor Conference

by Scott Larrivee | Feb 26, 2024 | News

VALENCIA, Calif. – February 26, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, today announced it will participate in a presentation and panel at the B. Riley Securities Radiopharma Investor Conference in New York City on...